Chronic Myeloid Leukaemia (CML) is often seen as one of the great success stories in rare disease, but the next chapter is only just beginning.

Chronic Myeloid Leukaemia (CML) is often seen as one of the great success stories in rare disease, but the next chapter is only just beginning. With targeted therapies now enabling many patients to live longer and more stable lives, it can be easy to assume the major challenges are behind us. But for patients living with CML today, the reality is more complex. Treatment resistance, symptom burden, and inequities in access to monitoring and support continue to shape outcomes, and not always in predictable ways.

Sanius Health believe progress in CML now depends on how well we can understand and respond to variation – between individuals, across treatment lines, and over time. Clinical trials remain a critical part of the picture, but they tell us little about how patients feel, function, or recover in the months and years that follow.

Sanius’ digital health ecosystem, MyCML+, was designed to address that gap. Built in partnership with patients and clinicians, it brings together symptom diaries, medication tracking, interaction checkers, biometric monitoring and progress logs, allowing each patient to monitor their condition while contributing to research-grade evidence that reflects their lived experience.

With a follow-up oral presentation scheduled at one of BOPA 2025’s plenary sessions later this year, Sanius’ initial findings highlighted at the British Society for Haematology (BSH2025) demonstrated the strength of this approach. Patients on second-line therapies reported significantly poorer outcomes than those on first-line, including higher levels of fatigue, muscle cramps, and pain, alongside lower EQ-5D-5L scores and general health ratings. Male patients also reported lower overall quality of life and greater symptom burden across pain and mobility, despite wearable data showing higher activity levels and lower average heart rates. These patterns expose a critical mismatch between physical activity and perceived wellbeing – blind spots that conventional datasets routinely miss.

At the European Haematology Association (EHA2025) Congress, Sanius were able to expand and validate these findings in a broader context. The relationship between biometric resilience and symptom perception was again clear, reinforcing the need to move beyond episodic data capture and towards continuous, patient-centred monitoring. Most importantly, the work highlighted that variation in experience is not a side note – it is central to delivering meaningful outcomes in CML. Understanding that variation is the first step to closing gaps in care.

This is where real-world infrastructure truly makes a difference. For patients, visibility into their health builds confidence and agency. For clinical teams, continuous insight enables earlier intervention, clearer decision-making, and improved alignment with patient priorities. For researchers, it offers a scalable foundation for understanding treatment response, symptom trajectories, and subgroup variation. And for industry and policy teams, it provides the kind of longitudinal, pre- and post-initiation evidence increasingly required to support reimbursement, HTA submissions, and post-marketing value demonstration.

MyCML+ provides an easily patient-accessible interface that goes beyond an app and creates a live, structured ecosystem designed to keep patients well, reduce unnecessary burden on clinical services, and generate research-ready data from day one. It reflects the same model Sanius has applied across rare and chronic conditions – from sickle cell disease and myeloma to haemophilia and myeloproliferative neoplasms – adapting to each patient community while maintaining the same core infrastructure and governance.

As Sanius continues to expand its CML cohort and add longitudinal follow-up across treatment lines, its goal remains clear: deliver real insights that drive better care. The promise of CML therapies is clear. The challenge now is turning that promise into reality for every patient, in every setting, every day.

For those interested in learning more about Sanius’ work in CML and across haematology, please reach out to their team at info@saniushealth.com.